People research BPC-157 and KPV together because they show up in the same online “healing and anti-inflammatory” protocols, often stacked. The comparison is less exciting than the marketing: on the two things that actually decide whether either is worth attention — how strong the evidence is and what the law says — the two peptides land close together, with one narrow but real difference. The table above is the row-by-row breakdown. Below is what each row means.
BPC-157 vs KPV: the short version
Both are research peptides with no published human randomized controlled trial, no approval in any major jurisdiction, and a shared date with the same FDA compounding committee in July 2026. The one meaningful gap is depth of evidence: BPC-157 has a large animal corpus plus a thin layer of human data, while KPV’s indexed record is preclinical only. If you are choosing between them hoping one is clearly proven, the data does not support that framing.
Evidence: one preclinical, one barely human
Most of what is known about either molecule comes from non-human studies. BPC-157 has the larger preclinical base — a broad rodent corpus on tendon, gut and wound healing — and, on top of it, a small amount of human data: a couple of uncontrolled pilots and, as of 2026, one recruiting Phase 2 trial for acute hamstring strain. KPV’s record is effectively all in cell and animal models; none of the indexed human-level records describe a trial of KPV itself, so its human evidence base is essentially absent. Neither has a randomized controlled trial, which is the bar for “this works in people.” For how we weigh these tiers, see our how we grade evidence explainer, the full BPC-157 evidence and regulatory record, and the KPV evidence and regulatory record.
What each is studied for
The two are studied for overlapping but distinct reasons. BPC-157 is investigated as a cytoprotective, angiogenic agent in models of tendon, ligament and gut repair. KPV is the C-terminal tripeptide (Lys-Pro-Val) of α-MSH, studied for its anti-inflammatory action through the melanocortin pathway, mostly in models of inflammatory bowel disease and colitis, plus some wound-healing work. So they get stacked for “healing,” but the mechanisms under study are not the same — one is tissue-repair focused, the other inflammation focused.
Regulation: the same July 2026 vote
Both were removed from the FDA 503A “do not compound” list in April 2026, but that did not make them compoundable. That decision comes from the Pharmacy Compounding Advisory Committee, which votes on both molecules on July 23, 2026 — for BPC-157 the evaluated indication is ulcerative colitis, for KPV it is wound healing and inflammatory conditions. We track the meeting in the July 2026 FDA peptide meeting, explained. On anti-doping, BPC-157 is explicitly prohibited under the WADA S0 category at all times; KPV is not individually named, but as a non-approved substance it falls under the same S0 catch-all. In the European Union, neither carries a marketing authorization.
So which one, if either?
The defensible answer in 2026 is that neither is an established human therapeutic, and the choice is between two unproven options for different mechanisms. The only concrete, sourced edge is that BPC-157 has any human data at all and a registered trial in progress, while KPV does not. Everything else — approval status, compounding status, anti-doping treatment — converges. Watch the July 2026 vote for the next real change.
Research information only. Neither BPC-157 nor KPV is approved for human use. Talk to a licensed physician before considering any peptide.